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Abstract Human data raised the possibility that coronary
heart disease is associated with mutations in the apolipopro-
tein gene cluster APOA1/C3/A4 that result in multideficiency
of cluster-encoded apolipoproteins and hypoalphalipopro-
teinemia. To test this hypothesis, we generated a mouse
model for human apolipoprotein A-I (apoA-I)/C-III/A-IV de-
ficiency. Homozygous mutants (Apoa1/c3/a42/2) lacking the
three cluster-encoded apolipoproteins were viable and fer-
tile. In addition, feeding behavior and growthwere apparently
normal. Total cholesterol (TC), high density lipoprotein cho-
lesterol (HDLc), and triglyceride levels in the plasmaof fasted
mutants fed a regular chow were 32% (P, 0.001), 17% (P,
0.001), and 70% (P , 0.01), respectively, those of wild-type
mice. When fed a high-fat Western-type (HFW) diet, Apoa1/
c3/a42/2 mice showed a further decrease in HDLc concen-
tration and amoderate increase inTC, essentially in non-HDL
fraction. The capacity of Apoa1/c3/a42/2 plasma to promote
cholesterol efflux in vitro was decreased to 75% (P, 0.001),
and LCAT activity was decreased by 38% (P , 0.01). Despite
the very low total plasma cholesterol, the imbalance in lipo-
protein distribution caused small but detectable aortic lesions
in one-third of Apoa1/c3/a42/2 mice fed a HFW diet. In con-
trast, none of the wild-type mice had lesions. These results
demonstrate that Apoa1/c3/a42/2 mice display clinical fea-
tures similar to human apoA-I/C-III/A-IV deficiency (i.e.,
marked hypoalphalipoproteinemia) and provide further
support for the apoa1/c3/a4 gene cluster as a minor suscep-
tibility locus for atherosclerosis in mice.—Mezdour, H., G.
Larigauderie, G. Castro, G. Torpier, J. Fruchart, M. Nowak,
J-C. Fruchart, M. Rouis, and N. Maeda. Characterization of a
new mouse model for human apolipoprotein A-I/C-III/A-IV
deficiency. J. Lipid Res. 2006. 47: 912–920.
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A strong inverse association exists between plasma high
density lipoprotein cholesterol (HDLc) levels and the
incidence of coronary artery disease in humans (1). The
major locus controlling HDLc levels is APOA1 (for apolipo-
protein A-I), a member of the apolipoprotein gene cluster
APOA1/C3/A4 (2). The cluster genes, APOA1, APOC3, and
APOA4, are evolutionarily related and tandemly organized
in a region of 17 kb DNA on human chromosome 11,
proximal to APOA5, a new member of the apolipoprotein
gene family (3). These APOA1/C3/A4 genes code for three
apolipoproteins, apoA-I, apoC-III, and apoA-IV, re-
spectively. ApoA-I is a 28 kDa protein synthesized in the
liver and small intestine (4). It is the major protein compo-
nent of HDL. Through its ability to promote cholesterol
efflux from cultured cells (5) and to activate LCAT (6),
apoA-I plays a key role in reverse cholesterol transport, a
mechanism postulated to prevent extrahepatic tissues from
accumulating excess cholesterol (7). Apolipoprotein C-III
is a 9 kDa protein produced predominantly in the liver. It
is a major component of plasma chylomicrons and VLDL.
ApoC-III inhibits the hydrolysis of triglyceride by lipopro-
tein lipase. Apolipoprotein A-IV is a 46 kDa protein asso-
ciated primarily with chylomicrons and HDL and is present
in the lipoprotein-free fraction of plasma (8). It is involved
in dietary fat absorption and likely in reverse cholesterol
transport (9, 10).
The contribution of the APOA1/C3/A4 gene cluster to
coronary heart disease has been recognized for nearly two
decades. Strong support came from rare human patients
with apoA-I/C-III or apoA-I/C-III/A-IV deficiencies (11,
12). These patients had very low HDL concentrations in
plasma and suffered from premature atherosclerosis. Also,
an association of a high risk for premature atherosclero-
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sis and lower plasma levels of apoA-I has been observed;
however, few mutations in the APOA1/C3/A4 gene cluster
that result in reduced levels or absence of apoA-I lead
to atherosclerosis (13). In contrast, single deficiencies
in apoA-I, apoC-III, and likely apoA-IV are not sufficient
to predispose mice to atherosclerosis (14–16), whereas
overexpression of human apoA-I (17) and apoA-IV (18)
but not apoC-III (19) had been reported to protect mice
from genetic or diet-induced atherosclerosis. In addi-
tion, simultaneous expression of apoA-I/C-III/A-IV in
mice induced marked hypertriglyceridemia and the ac-
cumulation of potentially atherogenic lipoproteins but
decreased susceptibility to atherosclerosis in an Apoe2/2
genetic background (20). Together, these observations
suggested a complex role of the apoa1/c3/a4 gene cluster,
as an integrated unit, in plasma lipoprotein metabolism
and atherosclerosis.
To begin to explore this issue, we generated a mouse
model for human apoA-I/C-III/A-IV deficiency by gene
targeting. In homozygous mutants, absence of apoA-I,
apoC-III, and apoA-IV from plasma was accompanied by
severe hypoalphalipoproteinemia and mild hypotriglycer-
idemia. In vitro analysis showed a reduced capacity of
plasma to promote cholesterol efflux and LCAT activity.
However, homozygous mutants displayed a limited sus-
ceptibility to atherosclerosis.
METHODS
Generation of apoA-I/C-III/A-IV-deficient mice
Mouse genomic DNA used for targeting vector was cloned
from a 129/Ola genomic library. The targeting construct con-
tains a 6 kb EcoRI-SacI fragment 59 to the apoa1 gene as 59 homol-
ogy and a 3 kb BamHI-HindIII fragment 39 of the apoa4 gene as
39 homology. Neomycin phosphotransferase and thymidine
kinase genes were used for positive/negative selection. A sub-
clone (BK4) of the mouse strain 129/Ola embryonic stem cell
line, E14TG2a, was cultured and electroporated with the tar-
geting construct, as described previously (21). The embryonic
stem cells surviving the positive/negative selection were ana-
lyzed by Southern blot after EcoRI digestion and hybridization to
a 1 kb probe from apoa4 intron 2. Targeted clones that carry a
13 kb deletion of the apoa1/C3/a4 gene cluster (Apoa1/c3/a4
allele) were identified by the presence of a 4.8 kb EcoRI frag-
ment, compared with a 15 kb wild-type fragment. Targeted em-
bryonic stem cells were microinjected into C57BL/6 blastocysts,
and resulting chimeric mice were mated with C57BL/6 mice to
generate F1 heterozygous mutants. Homozygous mutants were F2
generation animals derived from mating F1 Apoa1/c3/a41/2
mice. Tail DNA was digested with EcoRI, and Southern blots
were hybridized with the mouse apoa4 probe to identify mice
carrying the targeted allele. F2 generation mice with a 129/
Ola3C57BL/6 mixed genetic background were used for charac-
terization and experiments. Mice (8–10 weeks old) were matched
for age and gender, and wild-type littermates were used as con-
trols. Mice were housed in a temperature-controlled room with
alternating 12 h light (7 AM–7 PM) and dark periods. The ani-
mals had access to diet and water ad libitum. All procedures
involving animal handling and care were followed in accordance
with institutional guidelines.
Northern blot and real-time RT-PCR analysis
Total RNAs were extracted from tissues (liver and small in-
testine) with RNA-plus (Quantum), purified, and electropho-
resed (20 mg total RNA/lane) on 1% agarose gels containing
formaldehyde (22). Samples were blotted onto Hybond-N mem-
branes (Amersham Pharmacia Biotech, Saclay, France) and
hybridized with 32P-labeled cDNA-specific probes. For quantita-
tive PCR, reverse-transcribed apoA-V and apoE cDNA was quan-
tified by real-time PCR on a MX 4000 apparatus (Stratagene)
using specific oligonucleotide primers for apoa5 (59-CTC TGC
CCC ACA AAC TCA CAC G-39 and 59-AGG TAG GTG TCA TGC
CGA AAA G-39) and acidic ribosomal phosphoprotein 36B4 (59-
GGG AAG GTG TAA TCC GTC TCC ACA G-39 and 59-CAT GCT
CAA CAT CTC CCC CTT CTC C-39) to normalize the assay. The
forward primer used for mouse apoE was 59-CCG TGC TGT TGG
TCA CAT TGC TGA CAG GAT-39, and the reverse primer was 59-
GTT CTT GTG TGA CTT GGG AGC TCT GCA GCT-39.
Agarose gel and Western blot analysis
Agarose gel electrophoresis of plasma was performed on 1%
agarose gels (Sebia) after transfer of lipoproteins, and nitrocel-
lulose membranes were probed with rabbit polyclonal anti-
mouse apoA-I, apoC-III, or apoA-IV antibodies followed by a
conjugated goat anti-rabbit antibody (Pasteur Diagnostics). Che-
miluminescence (ECL System; Amersham Pharmacia Biotech)
was used for detection.
High-fat diet study
Mice (8–10 weeks old) with the indicated genotypes were
assigned to three groups. Group 1, or the control group (Apoa1/
c3/a41/1; n 5 15, 10 males and 5 females) and group 2 (Apoa1/
c3/a42/2; n 5 15, 10 males and 5 females) were fed a high-fat
Western-type (HFW) diet containing 0.2% cholesterol and 21%
fat (w/w) (UAR, Epinay sur Orge, France); group 3 (Apoa1/c3/
a42/2; n 5 8, 4 males and 4 females) was fed a standard chow diet
containing ,0.03% cholesterol and 5% fat (w/w) (UAR). The
HFW diet was continued for 16 weeks.
Plasma lipid and lipoprotein analysis
After a 5 h fast, the mice were anesthetized with avertin and
blood was collected from the retro-orbital sinus into microcen-
trifuge tubes containing EDTA. Plasma total cholesterol (TC)
and triglycerides were determined using diagnostic kits (Sigma
or Biomerieux) according to the instructions of the manufac-
turers. HDLc levels were determined in plasma after precipita-
tion of apoB-containing lipoproteins with dextran sulfate-Mg21
(23). TC and HDLc were first determined using homemade
standards constituted of pools of mouse plasma. Nevertheless,
these standards underestimated both HDL and TC concentra-
tions. Therefore, the final values reported here were obtained
after correction with coefficient factors determined after addi-
tional calibrations of our initial standards with a commercial
standard (Roche). For gel filtration analysis with fast-protein
liquid chromatography (Amersham Pharmacia Biotech), equal
volumes of plasma samples from the indicated genotypes were
pooled, 200 ml was fractionated using two serially linked Su-
perose 6 HR and Superose 12 HR columns, and TC was de-
termined in 100 ml of each collected fraction using an enzymatic
method (Sigma).
Analysis of plasma metabolic activity
Rat Fu5AH hepatoma cells, which have a high expression level
of scavenger receptor class B type I (SR-BI), and J774 mouse
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macrophages, which express ABCA1 and SR-BI at very low levels,
were used to assess cholesterol efflux, as described previously
(24), except that J774 cells were not pretreated with cAMP, a
molecule that upregulates ABCA1 gene expression. [3H]choles-
terol-loaded cells were incubated for 3 h with 2.5% diluted
plasma. All efflux values are reported as averages of at least three
determinations in different wells. Isolated human HDL samples
were included in each assay as positive controls. LCAT activity
was determined using the exogenous proteoliposome substrate
method with 25 ml of plasma from female mice (20). Experi-
ments were repeated twice with three different pools of sam-
ples for controls and mutants (coefficient of variation ,5%).
Histological analysis
Mice were euthanized, and the hearts were perfused from the
apex with a cold Krebs-Ringer buffer and fixed in a fixative con-
taining 4% paraformaldehyde in PBS, pH 7.4. The hearts, con-
taining the aortic origin, and other tissues (liver, lung, etc.) were
carefully removed and fixed in paraformaldehyde overnight.
Serial cryosections were obtained from tissues and stained using
Oil Red O and hematoxylin (25).
Statistical analysis
Results are expressed as means 6 SD. In all experiments, non-
transgenic littermates of each line were used as controls. Statisti-
cal differences in apolipoprotein and lipid levels between different
groups of animals were evaluated using Student’s two-tailed t-test,
unless indicated otherwise. Group differences or correlations with
P , 0.05 were considered statistically significant.
RESULTS
ApoA-I/C-III/A-IV-deficient mouse
To ensure total ablation of the apoa1/c3/a4 gene cluster,
a gene-targeting vector was constructed such that homol-
ogous recombination would delete 13 kb of the mouse’s
endogenous cluster, including the three apoa1 coding
exons, the entire apoc3 gene, intergenic regions, and the
first two exons of apoa4 (Fig. 1A, B). Loss of expression of
the cluster genes was demonstrated by Northern blot
analysis of total liver and intestine mRNA (Fig. 1C), and
the absence of apoA-I, apoC-III, and apoA-IV proteins from
plasma was demonstrated by Western blot analysis using
specific anti-mouse apolipoprotein antisera (Fig. 2B).
Therefore, we consider the Apoa1/c3/a42/2 a functional
null. Animals homozygous for the ablated cluster genes
appeared healthy and have apparently normal growth and
feeding behavior.
ApoA-I/C-III/A-IV deficiency causes dyslipidemia
On chow diet, total plasma TC and HDLc concentra-
tions were lower than those of wild-type littermates by 68%
and 83%, respectively. Their triglyceride concentration was
lower by 29% compared with normal controls, but the
decrease was statistically significant only in females
(Table 1). The mean ratio of TC to HDLc was 2.6 in
Apoa1/c3/a42/2 versus 1.4 in Apoa1/c3/a41/1, reflecting
a severe reduction of HDLc. Severe hypoalphalipopro-
teinemia was also demonstrated by agarose gel electro-
phoresis showing reduced a fraction of lipoproteins
(Fig. 2A). Plasma lipid levels did not change significantly
with age or gender (data not shown).
Plasma samples from several mice of each apoa1/c3/
a4 genotype were pooled and applied to the Superose 6
and 12 columns to fractionate the lipoproteins by size
(Fig. 3A). In wild-type mice fed regular chow diet, the
major lipoprotein eluted in the region corresponding to
HDL. Only a small amount of cholesterol was found in
regions corresponding to VLDL, intermediate density lipo-
protein (IDL), and LDL. Both male and female homo-
zygous mutants had similar lipoprotein profiles, which
demonstrates a dramatically reduced amount of choles-
terol in the HDL fraction (Fig. 3A).
Fig. 1. Targeted disruption of the mouse apolipoprotein
gene cluster apoa1/c3/a4. A: Schematic representation of
the gene-targeting strategy. a: The mouse apoa1/c3/a4 gene
cluster (wild-type allele). b: Targeting construct containing
genes for neomycin phosphotransferase (neo) and herpes
simplex virus thymidine kinase (TK) used for selection, and
59 and 39 regions of homology. c: The resulting targeted
allele. The sizes of diagnostic fragments are shown between
the EcoRI sites. B, BamHI; H, HindIII; R, EcoRI; S, SacI. B:
Southern blot analysis of tail DNA digested with EcoRI and
hybridized with the mouse apoa4 probe to identify F2
generation mice carrying the targeted allele. The 15 kb
hybridyzing EcoRI fragment indicates the wild-type allele,
and the 4.8 kb fragment indicates the mutated allele. C:
Northern blot analysis. Total RNA from liver and intestine
of each genotype was subjected to electrophoresis, and
expression of the cluster genes was examined using specific
cDNA probes for mouse apoa1, apoc3, and apoa4. Mouse b-
actin was used as the loading control.
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Response to the high-fat diet
When fed a HFW diet for 16 weeks, wild-type and homo-
zygous mutant animals responded differently (Table 2). In
Apoa1/c3/a42/2 males and females, TC increased by 52%
and 39%, whereas HDLc decreased by 7- and 2.5-fold,
respectively. In Apoa1/c3/a41/1 males and females, TC in-
creased by 72% and 50%, with increases in HDLc of 19%
and 9%, respectively. The TC/HDLc ratio increased to
28.6 in Apoa1/c3/a42/2 males compared with 1.7 in Apoa1/
c3/a41/1 males and increased to 8.6 in Apoa1/c3/a42/2
females versus 2.2 in Apoa1/c3/a41/1 females, suggesting
a further imbalance of plasma cholesterol distribution in
Apoa1/c3/a42/2 mice. In contrast, plasma triglyceride levels
were less affected by the high-fat diet in either normal or
mutant animals.
A 16 week high-fat diet resulted in an increase in the
lipoprotein fractions eluting in the VLDL/IDL region and
a further decrease in the HDL fraction in Apoa1/c3/a42/2
mice (Fig. 3B). The increase in TC, therefore, was mainly
the result of increased VLDL/IDL cholesterol, as con-
firmed by the increase in the preb fraction of lipoproteins
on agarose gel electrophoresis (Fig. 2A). Mice tolerated
high fat without obvious distress.
Impaired plasma metabolic activity
In the Fu5AH cell model, plasma from Apoa1/c3/a42/2
mice promoted cholesterol efflux, a pathway that involves
SR-BI, 4-fold less efficiently than Apoa1/c3/a41/1 mouse
plasma (4.1 6 1.2% vs. 16.3 6 3.4% in males and 7.1 6
2.6% vs. 15.4 6 2.2% in females; P , 0.001 and 0.01,
respectively) (Fig. 4A). In the J774 macrophage model, the
capacity of Apoa1/c3/a42/2 plasma for cholesterol efflux,
which is mediated mostly through ABCA1 and to a less
extent by SR-BI, was 65% that of wild-type plasma (6.3 6
0.8% vs. 9.6 6 1.1% in males and 6.5 6 1.1% vs. 9.2 6 0.9%
in females; P , 0.01) (Fig. 4B). Similarly, up to a 45%
decrease in LCAT activity was observed in Apoa1/c3/a42/2
mice compared with Apoa1/c3/a41/1 mice (11.2 6 2.2%
vs. 18.1 6 1.7% in males and 8.9 6 2.3% vs. 19.9 6 1.8% in
females; P , 0.01) (Fig. 4C).
Histology
No atherosclerotic lesions were observed in Apoa1/c3/
a42/2 mice maintained on regular chow (n = 8), even in
two homozygotes older than 10 months of age. In contrast,
small atherosclerotic lesions were present in the aortas of
4 males out of 10 and 1 female out of 5 Apoa1/c3/a42/2
mice fed a HFW diet for 16 weeks. These lesions were
limited to fatty streaks with small populations of foam
cells near the aortic valve attachment sites (Fig. 5A, B). No
lesion was observed in wild-type controls fed the same
high-fat diet (n 5 15). A complete necroscopy of Apoa1/
c3/a42/2 and Apoa1/c3/a41/1 mice was performed to de-
termine other morphologic changes secondary to ablation
of the apoa1/c3/a4 gene cluster. No gross histopatholog-
ical differences from normal animals were found in tissues
ofApoa1/c3/a42/2 animals fed a chow diet, such as the lung,
TABLE 1. Concentration of plasma lipids in mice fed a normal chow diet
Genotype Gender TC HDLc Triglycerides TC/HDLc
mg/dl
Apoa1/c3/a41/1 Male 69.3 6 11.9 (9) 56.3 6 15.2 (8) 53.5 6 9.2 (5) 1.2
Female 82.5 6 21.5 (4) 51.0 6 8.5 (2) 68.8 6 17.7 (4) 1.6
Apoa1/c3/a42/2 Male 24.4 6 6.0a (9) 8.8 6 2.3sa (8) 45.8 6 8.6 (9) 2.8
Female 23.4 6 7.7a (5) 9.4 6 3.3a (5) 37.6 6 4.2b (5) 2.4
HDLc, high density lipoprotein cholesterol; TC, total cholesterol. Data are means 6 SD. Numbers of mice are
indicated in parentheses.
aP , 0.001, Apoa1/c3/a42/2 versus Apoa1/c3/a41/1 matched for gender.
bP , 0.01, Apoa1/c3/a42/2 versus Apoa1/c3/a41/1 matched for gender.
Fig. 2. Agarose gel electrophoresis and Western blot analysis. A:
Plasma samples from mice fed a chow diet or a high-fat Western-type
(HFW) diet were electrophoresed on 1% agarose gels. Gels were
stained with Sudan black after drying. The positions a, b, preb, and
O correspond to HDL, LDL, VLDL, and origin, respectively. B: Im-
munoblots of lipoprotein fractions after transfer from agarose gels
using specific antibodies to mouse apolipoprotein A-I (apoA-I),
apoC-III, and apoA-IV.
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kidney, spleen, and liver (Fig. 5C, D). Feeding a high-fat diet
to wild-type mice for a long period caused severe fatty
changes in their livers (Fig. 5E). Thus, wild-type livers were
enlarged and pale. The hepatocytes in the wild-type livers
were enlarged with microvesicular lipid deposits. In
contrast, Apoa1/c3/a42/2 mice fed the same diet have
relatively normal livers. Histologically, the Apoa1/c3/a42/2
liver had very few lipid-laden cells (presumably Kupffer
cells) in the sinusoidal spaces surrounding hepatocytes, with
essentially normal appearance (Fig. 5D). In marked
contrast, most of the Apoa1/c3/a42/2 male and female
mutants had enlarged spleens, and severe splenomegaly was
observed in 4 out of 15 mice (3 males and 1 female) fed a
HFW diet (Fig. 5F).
DISCUSSION
In this study, we investigated the role of the apoa1/c3/a4
gene cluster in plasma lipoprotein metabolism in mouse.
Like humans with apoA-I/C-III/A-IV deficiency, the
Apoa1/c3/a42/2 mutants showed severe hypoalphalipo-
proteinemia, mild hypotriglyceridemia, and an apparent
decrease in non-HDL particles corresponding to b- and
preb fractions of lipoproteins (Fig. 2A). In contrast to
cluster-deficient patients, however, combined deficiencies
of apoA-I, apoC-III, and apoA-IV did not predispose mice
to severe atherosclerosis. It is well established that mice are
naturally resistant to spontaneous atherosclerosis. The
most susceptible strain is C57BL/6, which develops fatty
lesions only when fed a high-fat diet (15% fat, 1.5%
cholesterol, with 0.5% cholate) (25). In this study, Apoa1/
c3/a42/2 mice were fed a less toxic and more physiological
“Western-type” diet containing 21% fat and 0.2% choles-
terol without cholate. This diet is not atherogenic in wild-
type mice even in a susceptible C57BL/6 strain, although
it accelerates lesion formation in genetically predisposed
mice such as LDL receptor-deficient mice and apoE-
deficient mice (26). Interestingly, despite having only
30 mg/dl total plasma cholesterol, one-third of Apoa1/c3/
a42/2 mice fed a HFW diet developed small but detectable
aortic lesions. Although this heterogeneity may be attrib-
utable to their genetic background (F2 between C57BL/6
and 129/Ola), this suggests that the increased TC/HDLc
ratio contributes to the atherosclerosis in Apoa1/c3/a42/2
mice. Although additional studies are clearly necessary,
these observations suggest a possible contribution of the
apoa1/c3/a4 gene cluster to atheroprotection.
When fed a HFW diet, plasma cholesterol levels in
Apoa1/c3/a42/2 mice were less affected than in Apoa1/c3/
a41/1 normal controls. Although cholesterol levels in
normal male and female mice increased by 72% and 50%,
respectively, mostly in VLDL, IDL, and LDL fractions and
less so in HDL, these levels increased in Apoa1/c3/a42/2
mice by only 52% and 39%, respectively, exclusively in the
VLDL/LDL range of lipoproteins. One possible explana-
tion for the smaller increase in non-HDLc in the mutants
fed a HFW diet is that mice lacking apoA-I/C-III/A-IV
could have a poorer absorption of fat compared with nor-
TABLE 2. Concentration of plasma lipids in mice fed a HFW diet
Genotype Gender TC HDLc Triglycerides TC/HDLc
mg/dl
Apoa1/c3/a41/1 Male 119.3 6 57.1 (8) 69.2a 28.0 6 10.1 (8) 1.7
Female 124.2 6 39.8 (4) 55.8a 26.1 6 11.3 (4) 2.2
Apoa1/c3/a42/2 Male 37.2 6 15.0b (10) 1.3a 24.9 6 8.4 (10) 28.6
Female 32.6 6 11.4b (5) 3.8a 28.4 6 3.7 (5) 8.6
HFW, high-fat Western-type. Data are means 6 SD. Numbers of mice are indicated in parentheses.
a Measured in pooled samples.
bP , 0.001, Apoa1/c3/a42/2 versus Apoa1/c3/a41/1 matched for gender and diet.
Fig. 3. Lipoprotein profiles. Pooled plasma (200 ml) from homo-
zygous male mutants and wild-type male controls fed a normal
chow diet (A) or a HFW diet (B) was fractionated by gel filtra-
tion chromatography on Superose 6B columns. Fractions were
collected, and total cholesterol was measured by an enzymatic assay
in each fraction. IDL, intermediate density lipoprotein.
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mal mice. Support for the possible involvement of apoA-
IV in the intestinal absorption of fat comes from the
observation that the secretion of apoA-IV is increased
during fat absorption (27) and in patients with apoA-I/C-
III/A-IV deficiency, in whom an abnormal absorption of
fatty acids was observed (12). In contrast, patients with
apoA-I/C-III deficiencies have normal lipid absorption
(11). Thus, despite apparently normal feeding behavior
and growth, Apoa1/c3/a42/2 mice have a defective metab-
olism in the non-HDL fraction of lipoproteins, which
suggests either a faster catabolism of apoC-III-deficient
lipoproteins and/or abnormal lipid absorption and lipo-
protein synthesis.
The protective mechanism of HDL with respect to coro-
nary heart disease is believed to reside in its ability to pro-
mote cholesterol efflux from peripheral tissues, a key
process in reverse cholesterol transport, a mechanism pos-
tulated to prevent extrahepatic tissues from accumulating
excess cholesterol (7, 28). Efflux of cholesterol occurs via
multiple mechanisms: aqueous diffusion, SR-BI, or ABCA1.
Both diffusion-mediated and SR-BI-mediated efflux occur
to phospholipid-containing acceptors. In both cases, the
flux of cholesterol is bidirectional, with the direction of
net flux depending on the cholesterol gradient. In con-
trast, efflux via ABCA1 is unidirectional and mediates
the cellular efflux of phospholipids and cholesterol to
lipid-poor apolipoproteins. The ABCA1-mediated process
plays a significant role in the formation of nascent HDLs
and facilitates the removal of additional excess cellular
cholesterol, which is esterified by LCAT. The relative im-
portance of the SR-BI and ABCA1 efflux pathways in
preventing the development of atherosclerotic plaque is
not known but will depend on the expression levels of
the two proteins and on the type of cholesterol acceptors
available. A number of apolipoproteins have been impli-
cated in the process of promoting the efflux of free cho-
lesterol from the macrophages, including apoA-I, apoA-IV,
and apoE. Cholesterol efflux is significantly impaired in
cluster knockout mice but had only a limited effect on
atherosclerosis susceptibility. These results suggest that,
in addition to apoA-I/C-III/A-IV deficiency, a further
imbalance in lipoprotein distribution (i.e., an increase in
atherogenic lipoprotein level) is the primary factor af-
fecting cholesterol homeostasis in peripheral tissues
leading to foam cell formation. One can also speculate
that a limitation in atherosclerosis susceptibility in Apoa1/
c3/a42/2 mice could be related to apoE. It is well known
that lipid transport in mice is highly dependent on apoE
(26, 29), a protein that is produced by various tissues (30).
There were no alterations in the apoE levels in Apoa1/c3/
a42/2 mice compared with wild-type mice (data not
shown). It was observed that macrophage-derived apoE
exerts antiatherogenic properties largely independent of
its concentration in plasma and effects on plasma lipo-
proteins, likely through its contribution to cholesterol
efflux from macrophages. Indeed, transplantation of wild-
type bone marrow or the selective expression of a human
apoE transgene in macrophages decreased atherosclerosis
in apoE-deficient mice (31). Therefore, decreased choles-
terol influx caused low total and LDL-cholesterol, and an
efficient apoE-mediated cholesterol efflux may limit
atherogenesis in apoA-I/C-III/A-IV deficiency.
Other known genetic determinants associated with apoA-I
deficiency and hypoalphalipoproteinemia are Lcat and
Abca1 (1, 32). Indeed, like Apoa1/c3/a42/2 and Apoa12/2
mice, Lcat2/2 and Abca12/2 mice display marked decreases
in plasma levels of TC (z70%) and HDLc (z80–90%) in
homozygous mutants (33–35), but a decrease in triglyce-
ride level was observed only in apoC-III deficiency, secondary
to apoc3 gene deletion in Apoa1/c3/a42/2 mice or down-
expression in Apoa12/2 mice (Table 3). Downexpression of
apoc3, but not apoa4, results from interference by the near-
by neomycin resistance cassette (14, 21). In contrast, apoa5
gene expression was found to be normal in Apoa1/c3/a42/2
Fig. 4. Plasma metabolic activities. A, B: Plasma capacity to induce
cellular cholesterol efflux was determined using Fu5AH hepa-
toma cells (A) and J774 cells (B). A 2.5% dilution of plasma from
Apoa1/c3/a41/1 controls (open bars) and Apoa1/c3/a42/2 mutants
(hatched bars) fed a HFW diet for 16 weeks was incubated for 3 h
with [3H]cholesterol-labeled cells. Data are from representative
experiments with triplicate wells. C: LCAT activity was determined
in triplicate according to an exogenous substrate method. Values
are expressed as means 6 SD. ** P , 0.001, *** P , 0.01 as deter-
mined by the Mann-Whitney nonparametric test.
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mice (data not shown) and so likely in Apoa12/2 mutants,
consistent with transgenic studies showing that the apoC-III
enhancer regulates the expression of apoA-I, apoC-III,
and apoA-IV but not apoA-V in vivo (36). These data
demonstrate that Apoa12/2 mice are apoA-I/C-III-deficient
and differ from Apoa1/c3/a42/2 mice mostly by the pres-
ence of apoA-IV. However, like Abca12/2 and Lcat2/2 mice,
Apoa12/2 mutants displayed susceptibility to atherosclero-
sis only in severe hypercholesterolemia (i.e., in the Apoe2/2
or Ldlr2/2 background) (37–39), whereas Apoa1/c3/a42/2
mutants developed small atherosclerotic lesions in less
atherogenic conditions. These results suggest that, despite
a minor contribution to plasma HDLc variation, apoA-IV
may play a significant role in atheroprotection. Further
comparative studies of these hypoalphalipoproteinemia
models (i.e., Apoa1/c3/a42/2 mice vs. Apoa12/2 mice) will
likely provide better insight into the specific roles of apoA-
IV in lipid metabolism and atherosclerosis.
HDL particles have been shown to protect LDL from
oxidative modification (40, 41), to suppress adhesion mol-
ecule expression, and to induce cyclooxygenase-2 in vas-
cular endothelium (42), properties that are believed to be
protective against atherosclerosis. The lower level of HDL
and the absence of apoA-I- and apoA-IV-containing par-
ticles in Apoa1/c3/a42/2 mice fed a HFW diet may increase
the oxidative modifications of apoB-containing lipopro-
teins and the physiological dysfunctions of vascular en-
dothelium. Moreover, these modified particles could be
cleared through extrahepatic tissues. Thus, it is interesting
that morphological examination of mice at necroscopy
revealed protection from fatty changes of hepatocytes
but enlarged spleens in Apoa1/c3/a42/2 mice. Prolonged
exposure to a high-fat diet increased the occurrence of
splenomegaly, an abnormality that was also reported in
patients with Tangier disease (32) and in ABCA1-deficient
mice (34), although not yet in human apoA-I/C-III/A-IV
deficiency. Although the mechanism leading to spleno-
megaly-associated hypoalphalipoproteinemia has not
been identified, one hypothesis involves a dysfunction in
cholesterol efflux from macrophages.
Fig. 5. Morphological and histological evaluations. All mice were F2 between the C57BL/6 and 129/Ola genetic backgrounds. Lesion
occurrence was determined in sections from the proximal aorta near the aortic valve attachment sites. Sections of tissues are stained with Oil
Red O and counterstained with hematoxylin. A: Cross-section of an aortic sinus. The micrograph is from a 7 month old mouse fed a HFW
diet for 16 weeks. B: Small lesions, consisting mainly of foam cells, are observed in a Apoa1/c3/a42/2 (Aca2/2) mouse fed a HFW diet. C:
Liver section from a wild-type (Aca1/1) male fed a chow diet showing normal hepatocytes. D: Liver section from an Apoa1/c3/a42/2 male
mouse fed a HFW diet for 16 weeks, showing mild fatty changes of hepatocytes. E: Liver section from a wild-type male mouse fed a HFW diet
for 16 weeks, showing severe fatty changes of hepatocytes. F: Splenomegaly was observed in Apoa1/c3/a42/2 mice and was aggravated by
a HFW diet.
TABLE 3. Phenotypes of mouse models for hypoalphalipoproteinemia
Genotype ApoA-I ApoC-III ApoA-IV TC HDLc Triglycerides Aortic Lesions Ref.
Apoa1/c3/a42/2 0 0 0 32% 17% 70% HFW diet: 6
Apoa12/2 0 fl » 33% 20% 45% HFC diet: » Ldlr2/2: 1 (14, 21, 37)
Lcat2/2 fl n.r. n.r. ,30% ,7% z100% Ldlr2/2 or Apoe2/2: 1 (33, 38)
Abca12/2 fl n.r. n.r. ,30% ,5% z100% Ldlr2/2 or Apoe2/2: » Abca12BM/2BM, Apoe2/2: 1 (34, 35, 39)
ApoA-I, apolipoprotein A-I. Values shown are relative concentrations (percentage of wild-type controls); arrows indicate effects on plasma
apolipoproteins. Lesion formation was determined in mutants with the indicated genetic background, in bone marrow transplantation in the
Apoe2/2 background (Abca12BM/2BM, Apoe2/2), or in diet-induced hypercholesterolemia (HFC, high-fat and high-cholesterol diet containing
cholate). n.r., not reported; 1, increased susceptibility; 6, low susceptibility; », no effect on susceptibility.
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In summary, our findings demonstrate that Apoa1/c3/
a42/2 mice display marked hypoalphalipoproteinemia
and that apoA-I/C-III/A-IV deficiency has a profound
impact on plasma lipoprotein metabolism. However, in
contrast to humans, our results in mice suggest that hypo-
alphalipoproteinemia secondary to apoA-I/C-III/A-IV
deficiency requires additional genetic or environmental
risk factors that increase LDL-cholesterol level for the ini-
tiation of atherosclerosis.
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Pouilly, Isabelle Riva, Catherine Lasselin, Corinne Copin, and
Joelle Lepage for excellent technical assistance. This work was
supported in part by grants from the Fonds Européen de
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